Neumora Therapeutics, Inc.
NMRA · XNASCIK 1885522fmd_1H02YV34X97HKQCQP7G97N5VFVManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2022 to Jun 30, 2026, 18 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Realized investment gains (losses) | 0 | – | – | – |
| Research and development | 92 | 143 | 201 | 176 |
| Total operating expenses | 136 | 252 | 263 | 241 |
| Operating income | (136) | (252) | (263) | (241) |
| Interest expense | – | – | 0 | 2 |
| Interest and investment income | – | – | 20 | 8 |
| Other non-operating income (expense) | 5 | 16 | 20 | 4 |
| Income before taxes | (131) | (236) | (244) | (237) |
| Income tax expense | – | 0 | 0 | 0 |
| Net income from continuing operations | – | (236) | (244) | (237) |
| Net income | (131) | (236) | (244) | (237) |